Trial Profile
A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 08 Dec 2020 Samples from this study (n=40) were used to assess the utility of ctDNA in high-risk patients with DLBCL, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 15 Jul 2020 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results assessing utility of ctDNA in identifying high-risk pts with DLBCL, presented at the 25th Congress of the European Haematology Association